共 50 条
- [21] Preclinical validation of a novel CD133/CD3 bispecific T -cell engager (BiTE) antibody to target patient -derived glioblastoma cellsCANCER RESEARCH, 2016, 76Vora, ParvezVenugopal, ChitraAdams, JarrettPan, JamesChokshi, ChirayuQazi, MaleehaSubapanditha, MinomiSingh, MohiniBakhshinyan, DavidBezverbnaya, KseniaMcFarlane, NicoleBramson, JonathanSidhu, SachdevMoffat, JasonSingh, Sheila
- [22] A ROR1 SPECIFIC CD3 BISPECIFIC T-CELL ENGAGER ENGINEERED FOR SOLID TUMORS WITH AN EXPANDED THERAPEUTIC WINDOWJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A1110 - A1110Rabinovich, BrianZhou, XueyuanTakimoto, JeffreySong, PaulAlici, EvrenKhanna, Nikhita
- [23] A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivoLEUKEMIA, 2017, 31 (08) : 1743 - 1751Hipp, S.Tai, Y-TBlanset, D.Deegen, P.Wahl, J.Thomas, O.Rattel, B.Adam, P. J.Anderson, K. C.Friedrich, M.
- [24] A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivoLeukemia, 2017, 31 : 1743 - 1751S HippY-T TaiD BlansetP DeegenJ WahlO ThomasB RattelP J AdamK C AndersonM Friedrich
- [25] Combination of a Novel Fusion Protein CD3εζ28 and Bispecific T Cell Engager Enhances the Persistance and Anti-Cancer Effects of T CellsCANCERS, 2022, 14 (19)Yu, FengGao, YangWu, YanDai, AnranWang, XiaoyanZhang, XiangzhiLiu, GuodongXu, QinggangChen, Dongfeng
- [26] UMG1/CD3ε-bispecific T-cell engager redirects T-cell cytotoxicity against diffuse large B-cell lymphomaBRITISH JOURNAL OF HAEMATOLOGY, 2024, 204 (02) : 555 - 560Caracciolo, DanielePolera, NicolettaBelmonte, BeatriceConforti, FrancescoSignorelli, StefaniaGulino, AlessandroStaropoli, NicolettaTuccillo, Franca MariaBonelli, PatriziaJuli, GiadaGrillone, KatiaAscrizzi, SerenaCirillo, MariaMigale, LeonardoBallerini, AndreaPelizon, CristinaDi Martino, Maria TeresaTagliaferri, PierosandroRiillo, CaterinaTassone, Pierfrancesco
- [27] Phase I safety and efficacy of brenetafusp, a PRAME x CD3 ImmTAC T cell engager, in platinum resistant ovarian cancer (PROC)ANNALS OF ONCOLOGY, 2024, 35 : S569 - S570Friedman, C.Williams, A. De BurghLopez, J. S.Ouali, K.Middleton, M. R.Thistlethwaite, F.Hamid, O.Izar, B.Garcia, V. MorenoJohnson, M. L.Davar, D.Martin-Liberal, J.Roxburgh, P.Moore, K. N.Olson, D.Rottey, S.Kirk, P. B.Yuan, Y.Marshall, S.Yeku, O.
- [28] Immunodepletion of MDSC by AMV564, a novel bivalent, bispecific CD33/CD3 T cell engager, ex vivo in MDS and melanomaMOLECULAR THERAPY, 2022, 30 (06) : 2315 - 2326Cheng, PingyanChen, XianghongDalton, RobertCalescibetta, AlexandraSo, TinaGilvary, DanielleWard, GraceSmith, VictoriaEckard, SterlingFox, Judith A.Guenot, JeanmarieMarkowitz, JosephCleveland, John L.Wright, Kenneth L.List, Alan F.Wei, ShengEksioglu, Erika A.
- [29] Erratum: A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivoLeukemia, 2017, 31 : 2278 - 2278S HippY-T TaiD BlansetP DeegenJ WahlO ThomasB RattelP J AdamK C AndersonM Friedrich
- [30] Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical StudyBLOOD, 2022, 140Wong, Sandy W.Bar, NoffarParis, LauraHofmeister, Craig C.Hansson, MarkusSantoro, ArmandoMateos, Maria-VictoriaRodriguez-Otero, PaulaLund, JohanEncinas, CristinaYee, Andrew J.Oriol, AlbertCerchione, Claudiode la Rubia, JavierFerstl, BarbaraCarlson, KristinaRibas, PazBermudez, AranchaBoss, Isaac W.Gaudy, AllisonLi, ShaoyiHsu, KevinGodwin, Colin D.Burgess, Michael R.San-Miguel, JesusCosta, Luciano J.